Navigation Links
Aromatase inhibitor letrozole guards against breast cancer relapse for up to 8 years
Date:9/25/2011

Stockholm, Sweden: Results from the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole show unequivocally that letrozole has withstood the test of time and continues to prevent breast cancer recurrences and reduce the risk of death in post-menopausal women with hormone receptor-positive early breast cancer.

Professor Richard Gelber told delegates at the 2011 European Multidisciplinary Cancer Congress [1], in Stockholm today (Monday 26 September) that a 12-year update of results from the Breast International Group (BIG) 1-98 [2] trial showed that if women with early breast cancer (cancer that has not spread from the breast) were given letrozole after surgery for at least five years, they continued to do better and have fewer recurrences of the disease than those who were given tamoxifen.

"Over a median of eight years of follow-up, women who were assigned to receive five years of letrozole after surgery had an 18% reduced risk of relapse and a 21% reduced risk of death compared with those assigned to receive tamoxifen," said Prof Gelber, Director of the International Breast Cancer Study Group (IBCSG) Statistical and Data Management Center at the Dana-Farber Cancer Institute, Boston, MA, USA.

"The current 12-year update is the longest follow-up to date and includes much more information than we had after ten years. For instance, there have been 32% more relapses and 39% more deaths since the ten-year update, which increases substantially the reliability of the results and provides reassurance regarding the long-term value of letrozole. This additional follow-up and accumulation of information on relapses and deaths show that the overall survival advantage for adjuvant letrozole compared to tamoxifen continues to be statistically significant."

Adjuvant therapy (treatment that is given after surgery), using drugs that target hormones such as oestrogen, is given to patients with early breast cancer who
'/>"/>

Contact: Kay Roche
kayroche@gmail.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Study sheds light on aromatase inhibitor joint pain syndrome
2. University of Michigan scientists identify chemical in bananas as potent inhibitor of HIV infection
3. Patients Who Take a Proton-Pump Inhibitor With Medicine to Prevent Blood Clots Are Less Likely to Be Hospitalized for Bleeding Ulcers
4. BRAF inhibitor shows promising preclinical activity against melanoma
5. JAK inhibitor provides rapid, durable relief for myelofibrosis patients
6. Novel biomarker may predict response to new VEGF receptor inhibitor
7. Afatinib benefits lung cancer patients whose cancer progressed after treatment with EGFR inhibitors
8. PARP inhibitor, MK-4827, shows anti-tumor activity in first trial in humans
9. JAK inhibitors producing significant response in myelofibrosis patients
10. Current smokers with early rheumatoid arthritis less responsive to TNF inhibitors, methotrexate
11. Combining 2 peptide inhibitors might block tumor growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... history of snoring, apnea , , WEDNESDAY, June 11 (HealthDay News) ... a sleep-related breathing disorder, says a University of Virginia study. ... to 18 years, who were referred to a pediatric sleep ... an increased frequency of snoring. , The children,s neck size, ...
... been ruled out as source of contaminated tomatoes, they ... health officials said Wednesday they are zeroing in on ... contaminated tomatoes. , "The question is where specifically did ... for foods at the U.S. Food and Drug Administration ...
... Mayo Clinic research suggests unmarried women living in rural ... counterparts. This lower health status often includes greater instances ... study were recently published in the Journal of ... care physicians should take a proactive role in addressing ...
... Case Western Reserve University School of Medicine and Penn ... that reduces sterile inflammation within the cornea. Published in ... Biology, Dr. Eric Pearlman and Dr. Mark Kester ... delivered in nano-sized packages reduces corneal haze, corneal thickening ...
... of some NSAIDS, it could prevent buildup of plaque ... (HealthDay News) -- A class of drugs called gamma-secretase ... study suggests. , A hallmark of Alzheimer,s is so-called ... gamma-secretase modulators reduce the production of long pieces of ...
... Paris, France, Wednesday June 11th 2008: At least 50% ... state free of signs and symptoms) within 36 weeks ... in combination with tight control, according to results of ... Congress of the European League Against Rheumatism in Paris, ...
Cached Medicine News:Health News:Children's Neck Size Associated With Sleep Disorders 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 3Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 4Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks 2
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Amarin Corporation plc (Nasdaq: AMRN ... the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference ... will be held at the Nikko Hotel in San Francisco. ... be available at the following URL:   ...
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
Cached Medicine Technology:Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference 2Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: